Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propiverine is a small molecule antimuscarinic and calcium channel antagonist used primarily to treat symptoms of overactive bladder (OAB), including urinary urgency, frequency, and incontinence. It acts as a detrusor muscle relaxant by blocking muscarinic receptors in the bladder and modulating calcium influx into smooth muscle cells. This dual mechanism reduces involuntary contractions of the bladder muscle and increases bladder capacity. Propiverine is available as tablets and prolonged-release capsules for oral administration[2][3][5][6][8]. The drug was originally developed by Apogepha.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propiverine.